Literature DB >> 28967993

Production of Purified CasRNPs for Efficacious Genome Editing.

Emily Lingeman1,2, Chris Jeans3, Jacob E Corn1,2.   

Abstract

CRISPR-Cas systems have been harnessed as modular genome editing reagents for functional genomics and show promise to cure genetic diseases. Directed by a guide RNA, a Cas effector introduces a double stranded break in DNA and host cell DNA repair leads to the introduction of errors (e.g., to knockout a gene) or a programmed change. Introduction of a Cas effector and guide RNA as a purified Cas ribonucleoprotein complex (CasRNP) has recently emerged as a powerful approach to alter cell types and organisms. Not only does CasRNP editing exhibit increased efficacy and specificity, it avoids optimization and iteration of species-specific factors such as codon usage, promoters, and terminators. CasRNP editing has been rapidly adopted for research use in many contexts and is quickly becoming a popular method to edit primary cells for therapeutic application. This article describes how to make a Cas9 RNP and outlines its use for gene editing in human cells. © 2017 by John Wiley & Sons, Inc.
Copyright © 2017 John Wiley & Sons, Inc.

Entities:  

Keywords:  CRISPR; Cas9; RNP; genome editing; ribonucleoprotein

Mesh:

Substances:

Year:  2017        PMID: 28967993     DOI: 10.1002/cpmb.43

Source DB:  PubMed          Journal:  Curr Protoc Mol Biol        ISSN: 1934-3647


  13 in total

1.  A Genome-wide ER-phagy Screen Highlights Key Roles of Mitochondrial Metabolism and ER-Resident UFMylation.

Authors:  Jin Rui Liang; Emily Lingeman; Thao Luong; Saba Ahmed; Matthias Muhar; Truc Nguyen; James A Olzmann; Jacob E Corn
Journal:  Cell       Date:  2020-03-10       Impact factor: 41.582

2.  Preparation of Cas9 Ribonucleoproteins for Genome Editing.

Authors:  Sheng-Wei Lin; Viet Quoc Nguyen; Steven Lin
Journal:  Bio Protoc       Date:  2022-05-20

3.  Double stranded DNA breaks and genome editing trigger loss of ribosomal protein RPS27A.

Authors:  Celeste Riepe; Elena Zelin; Phillip A Frankino; Zuriah A Meacham; Samantha G Fernandez; Nicholas T Ingolia; Jacob E Corn
Journal:  FEBS J       Date:  2022-01-10       Impact factor: 5.622

4.  Endogenous Protein Tagging in Human Induced Pluripotent Stem Cells Using CRISPR/Cas9.

Authors:  Amanda Haupt; Tanya Grancharova; Joy Arakaki; Margaret A Fuqua; Brock Roberts; Ruwanthi N Gunawardane
Journal:  J Vis Exp       Date:  2018-08-25       Impact factor: 1.355

5.  The CUL5 ubiquitin ligase complex mediates resistance to CDK9 and MCL1 inhibitors in lung cancer cells.

Authors:  Shaheen Kabir; Justin Cidado; Courtney Andersen; Cortni Dick; Pei-Chun Lin; Therese Mitros; Hong Ma; Seung Hyun Baik; Matthew A Belmonte; Lisa Drew; Jacob E Corn
Journal:  Elife       Date:  2019-07-11       Impact factor: 8.140

6.  Co-expression of Cas9 and single-guided RNAs in Escherichia coli streamlines production of Cas9 ribonucleoproteins.

Authors:  Jie Qiao; Wenqiang Li; Siyu Lin; Wenli Sun; Lixin Ma; Yi Liu
Journal:  Commun Biol       Date:  2019-05-03

7.  Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 Ribonucleoproteins.

Authors:  Rih-Sheng Huang; Hsin-An Shih; Min-Chi Lai; Yao-Jen Chang; Steven Lin
Journal:  Front Immunol       Date:  2020-05-22       Impact factor: 7.561

Review 8.  Cutting back malaria: CRISPR/Cas9 genome editing of Plasmodium.

Authors:  Marcus C S Lee; Scott E Lindner; Jose-Juan Lopez-Rubio; Manuel Llinás
Journal:  Brief Funct Genomics       Date:  2019-09-24       Impact factor: 4.241

9.  Staphylococcus aureus Cas9 is a multiple-turnover enzyme.

Authors:  Paul Yourik; Ryan T Fuchs; Megumu Mabuchi; Jennifer L Curcuru; G Brett Robb
Journal:  RNA       Date:  2018-10-22       Impact factor: 4.942

10.  CRISPR-Cas9 interrogation of a putative fetal globin repressor in human erythroid cells.

Authors:  Jennifer E Chung; Wendy Magis; Jonathan Vu; Seok-Jin Heo; Kirmo Wartiovaara; Mark C Walters; Ryo Kurita; Yukio Nakamura; Dario Boffelli; David I K Martin; Jacob E Corn; Mark A DeWitt
Journal:  PLoS One       Date:  2019-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.